Andrea Breen
Adult Health · Albany, NYNPI 1073911590
Payments from drug & device makers
Across 18 payments — averaging $148.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$744
- Stemline Therapeutics Inc.$665
- Myriad Genetic Laboratories, Inc.$257
- Incyte Corporation$186
- Regeneron Healthcare Solutions, Inc.$145
- Exelixis Inc.$125
- plus $554 from 6 others
What the payments were for
- Consulting fees$1,16544%
- Food & beverage$1,24346%
- Education$26910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $744 |
| Stemline Therapeutics Inc. | 1 | $665 |
| Myriad Genetic Laboratories, Inc. | 2 | $257 |
| Incyte Corporation | 2 | $186 |
| Regeneron Healthcare Solutions, Inc. | 1 | $145 |
| Exelixis Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $114 |
| Tactile Systems Technology Inc | 2 | $113 |
| Seagen Inc. | 2 | $112 |
| Epizyme, Inc. | 1 | $65 |
| AbbVie | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,677 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZarxioFilgrastim-Sndz | 16 | $36,989 |
| OxycontinOxycodone Hcl | 15 | $6,681 |
| Exemestane | 18 | $4,021 |
| Letrozole | 82 | $1,090 |
| Oxycodone Hcl | 42 | $496 |
| Anastrozole | 39 | $480 |
| Ondansetron Hcl | 11 | $251 |
| Omeprazole | 14 | $194 |
| Tamoxifen Citrate | 13 | $175 |
| Dexamethasone | 14 | $174 |
| Levothyroxine Sodium | 18 | $89 |
| Famotidine | 15 | $68 |
| Alprazolam | 11 | $54 |
| Prednisone | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Other adult health in Albany
- Allison DrakeAlbany$17K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.